<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01227720</url>
  </required_header>
  <id_info>
    <org_study_id>NICTDP1076</org_study_id>
    <nct_id>NCT01227720</nct_id>
  </id_info>
  <brief_title>Comparative Pharmacokinetic Study of New Oral Nicotine Replacement Therapy Products.</brief_title>
  <official_title>Comparative Pharmacokinetic Study of New Oral Nicotine Replacement Therapy Products - A Study in Healthy Smokers.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>McNeil AB</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johnson &amp; Johnson Consumer and Personal Products Worldwide</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Comparative pharmacokinetic study of new oral nicotine replacement therapy products.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study compares new oral Nicotine Replacement Therapy (NRT) products containing 2 and 4
      mg nicotine with NiQuitin™ lozenge 2 mg and 4 mg, after 12 hours of nicotine abstinence, with
      respect to nicotine pharmacokinetics, during 12 hours after start of administration. Single
      doses of treatment A, B, C, and D are given once in the morning during separate treatment
      visits scheduled in a crossover setting with randomized treatment sequences, also including a
      fifth treatment visit with either treatment E or F. The study will include 104 healthy
      smokers between the ages of 19 and 50 years, who have been smoking at least 10 cigarettes
      daily during at least one year preceding inclusion. The study will be performed at two sites
      with 52 subjects at each site. Subjects and study personnel will be aware of which treatment
      is administered at a given visit.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2009</start_date>
  <completion_date type="Actual">January 2010</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Plasma Concentration</measure>
    <time_frame>during 12 hours after product administration</time_frame>
    <description>The maximum observed nicotine concentration in plasma (Cmax)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the Curve</measure>
    <time_frame>after 12 hours</time_frame>
    <description>The area under the plasma concentration-vs-time curve until the last measurable concentration (AUCt) and the area under the plasma concentration-vs.-time curve until infinity (AUC∞)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time of Maximum Concentration</measure>
    <time_frame>during 12 hours after start of product administration</time_frame>
    <description>The time of occurrence of maximum concentration (Tmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal Elimination Rate Constant</measure>
    <time_frame>during 12 hours after start of product administration</time_frame>
    <description>The terminal nicotine elimination rate constant (λz)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oral Dissolution Time</measure>
    <time_frame>from administration until completely dissolved</time_frame>
    <description>Actual time required for oral dissolution</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">104</enrollment>
  <condition>Tobacco Dependence</condition>
  <arm_group>
    <arm_group_label>A NSL2L</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Experimental Nicotine Replacement Therapy (NRT)(L) 2 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B Lozenge</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Marketed Nicotine Lozenge 2 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C NSL4M</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Experimental NRT (M) 4 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>D Lozenge</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Marketed Nicotine Lozenge 4 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>E NSL4L</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Experimental NRT (L) 4 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>F NSL4H</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Experimental NRT (H) 4 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Experimental Nicotine Replacement Therapy (NRT) 2 mg</intervention_name>
    <description>2 mg Single-dose of new NRT product (NSL2L)</description>
    <arm_group_label>A NSL2L</arm_group_label>
    <other_name>Not yet marketed</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Experimental Nicotine Replacement Therapy (NRT)</intervention_name>
    <description>4 mg Single-dose of new NRT product</description>
    <arm_group_label>C NSL4M</arm_group_label>
    <arm_group_label>E NSL4L</arm_group_label>
    <arm_group_label>F NSL4H</arm_group_label>
    <other_name>Not yet marketed</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Marketed Nicotine Lozenge</intervention_name>
    <description>2 mg Single-dose of marketed lozenge</description>
    <arm_group_label>B Lozenge</arm_group_label>
    <other_name>NiQuitin™ lozenge</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Marketed Nicotine Lozenge</intervention_name>
    <description>4 mg Single-dose of marketed lozenge</description>
    <arm_group_label>D Lozenge</arm_group_label>
    <other_name>NiQuitin™ lozenge</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy subjects, smoking at least 10 cigarettes daily during at least one year
             preceding inclusion and BMI between 17.5 and 30.0 kg/m2.

          -  Female participants of child-bearing potential are required to use a medically
             acceptable means of birth control.

          -  A personally signed and dated informed consent document, indicating that the subject
             has been informed of all pertinent aspects of the study.

        Exclusion Criteria:

          -  Pregnancy, lactation or intended pregnancy.

          -  Treatment with an investigational product or donation or loss of blood within 3 month
             preceding the first dose of study medication.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elisabeth Kruse, PhD</last_name>
    <role>Study Director</role>
    <affiliation>McNeil AB</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Lund University Hospital Clinical Trial Unit</name>
      <address>
        <city>Lund</city>
        <zip>SE-221 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McNeil AB Clinical Pharmacology R&amp;D</name>
      <address>
        <city>Lund</city>
        <zip>SE-222 20</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 22, 2010</study_first_submitted>
  <study_first_submitted_qc>October 22, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 25, 2010</study_first_posted>
  <last_update_submitted>July 6, 2012</last_update_submitted>
  <last_update_submitted_qc>July 6, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 10, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Smoking Cessation, Nicotine pharmacokinetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tobacco Use Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nicotine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

